^
Association details:
| Biomarker: | MGMT unmethylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | temozolomide (DNA synthesis inhibitor) + veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
Published date:
05/13/2021
Excerpt:
...patients with newly diagnosed glioblastoma and MGMT-unmethylated promotor status. The experimental arm consisted of veliparib and radiotherapy, followed by adjuvant veliparib and temozolomide....PFS-6m was 46% (95% confidence interval [CI]: 36–57%) in the experimental arm and 31% (95% CI: 18–46%) in the standard arm....The veliparib-containing regimen was feasible and well tolerated.
DOI:
https://doi.org/10.1093/neuonc/noab111
